DiscoverThe AMR StudioEp 57: Olivier Rubin & AMR governance. November update. Rifaximin & daptomycin cross-resistance.
Ep 57: Olivier Rubin & AMR governance. November update. Rifaximin & daptomycin cross-resistance.

Ep 57: Olivier Rubin & AMR governance. November update. Rifaximin & daptomycin cross-resistance.

Update: 2024-12-03
Share

Description

Hitting this November month with a very relevant topic, Global Governance! In this episode, you can listen to an interview with had with Prof. Olivier Rubin, from Roskilde University in Denmark, about the social dimensions of AMR, and how AMR is a so-called “creeping crisis” globally. Olivier has years of experience researching slow-onset crisis such as famine and climate change, and has in the recent years worked intensively in AMR and the similarities and differences with such crises. Tune in to hear his insights!

In the news section, we update you on our very very busy month of November, and bring you a really important paper demonstrating the relationship between rifaximin use and daptomicin resistance in Enterococcus.

Check relevant links in the show notes here. Follow our updates on ⁠twitter/X & Bluesky⁠ with #theAMRstudio hashtag! Theme music by ⁠Henrik Niss⁠.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ep 57: Olivier Rubin & AMR governance. November update. Rifaximin & daptomycin cross-resistance.

Ep 57: Olivier Rubin & AMR governance. November update. Rifaximin & daptomycin cross-resistance.

Uppsala Antibiotic Center